whole blood; serum; serum-derived exosomes; NSCLC tissues; neighboring normal tissues; tumor tissues
BEAS-2B; A549; H292; 293T
cell line-derived xenograft
ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); glycolysis (promotes)
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; MTT; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; Western Blot; Bioinformatics Analysis
Potential NSCLC diagnostic biomarker and therapeutic target.
circARHGAP10 is upregulated in NSCLC tissues, cells, serum, and serum-derived exosomes. It promotes NSCLC proliferation, migration, invasion, glycolysis, and xenograft tumor growth by sponging miR-638 and increasing FAM83F expression, suggesting potential biomarker and therapeutic relevance.
0.7795
Serum-Derived Exosomes-Mediated Circular RNA ARHGAP10 Modulates the Progression of Non-Small Cell Lung Cancer Through the miR-638/FAM83F Axis.
combined biological and clinical study